Potent inhibitor scaffold against Trypanosoma cruzi trans-sialidase

Area of Science:

• Parasitology
• Drug Discovery
• Biochemistry

Background:

• Chagas disease, caused by Trypanosoma cruzi, is a life-threatening parasitic infection.
• T. cruzi trans-sialidase (TcTS) is a validated drug target, but existing inhibitors lack sufficient potency.
• Current TcTS inhibitors, often sialic acid derivatives or DANA analogues, exhibit weak IC(50) values (hundreds of micromolar).

Purpose of the Study:

• To identify novel, potent inhibitors of T. cruzi trans-sialidase (TcTS) from a natural product library.
• To explore the potential of natural products as lead scaffolds for Chagas disease chemotherapeutics.

Main Methods:

• Screening of a natural product library for TcTS inhibitory activity.
• Structure-activity relationship (SAR) analysis of identified flavonoid and anthraquinone derivatives.
• Evaluation of inhibitor specificity for TcTS.

Main Results:

• Flavonoid and anthraquinone derivatives were identified as promising TcTS inhibitors.
• Apigenin was found to possess the minimal effective structure for TcTS inhibition and exhibits trypanocidal activity.
• A specific anthraquinone derivative, 6-chloro-9,10-dihydro-4,5,7-trihydroxy-9,10-dioxo-2-anthracenecarboxylic acid, demonstrated the highest TcTS inhibitory activity reported to date.
• The anthraquinone derivative's inhibition was specific to TcTS.

Conclusions:

• Natural products, particularly apigenin and a novel anthraquinone, represent potent lead scaffolds for developing new anti-Chagas disease drugs.
• These compounds offer improved therapeutic potential compared to existing TcTS inhibitors.
• Further development of these natural product derivatives could lead to effective chemotherapeutics against Chagas disease.